Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel <i>In Silico</i> Method

Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel <i>In Silico</i> Method

The SARS-CoV-2 outbreak caused an unprecedented global public health threat, having a high transmission rate with currently no drugs or vaccines approved. An alternative powerful additional approach to counteract COVID-19 is <i>in silico</i> drug repurposing. The SARS-CoV-2 main protease...

Full description

Bibliographic Details
Main Authors:	Milan Sencanski, Vladimir Perovic, Snezana B. Pajovic, Miroslav Adzic, Slobodan Paessler, Sanja Glisic
Format:	Article
Language:	English
Published:	MDPI AG 2020-08-01
Series:	Molecules
Subjects:	SARS-CoV-2 main protease M<sup>pro</sup> drug repurposing virtual screening ISM
Online Access:	https://www.mdpi.com/1420-3049/25/17/3830

Similar Items

In Silico and In Vitro Inhibition of SARS-CoV-2 PL<sup>pro</sup> with Gramicidin D
by: Sara Protić, et al.
Published: (2023-01-01)

Identification of SARS‐CoV‐2 Papain‐like Protease (PLpro) Inhibitors Using Combined Computational Approach**
by: Dr. Milan Sencanski, et al.
Published: (2022-02-01)

The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CL<sup>pro</sup> In Vitro
by: Raphael J. Eberle, et al.
Published: (2021-05-01)

Computer-Aided Prediction of the Interactions of Viral Proteases with Antiviral Drugs: Antiviral Potential of Broad-Spectrum Drugs
by: Pengxuan Ren, et al.
Published: (2023-12-01)

Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188
by: Gordon J. Lockbaum, et al.
Published: (2021-01-01)

Novel Small-Molecule Scaffolds as Candidates against the SARS Coronavirus 2 Main Protease: A Fragment-Guided in Silico Approach
by: Teresa L. Augustin, et al.
Published: (2020-11-01)

Quinazolinone-Peptido-Nitrophenyl-Derivatives as Potential Inhibitors of SARS-CoV-2 Main Protease
by: Huynh-Nguyet-Huong Giang, et al.
Published: (2023-01-01)

Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets
by: Pei-Chen Yu, et al.
Published: (2022-01-01)

The Potential of Usnic-Acid-Based Thiazolo-Thiophenes as Inhibitors of the Main Protease of SARS-CoV-2 Viruses
by: Olga I. Yarovaya, et al.
Published: (2024-01-01)

Synthesis of New <i>bis</i>-furanyl-pyrrolo[3,4-<i>b</i>]pyridin-5-ones via the Ugi-Zhu Reaction and Docking Studies on the Main Protease (M<sup>Pro</sup>) from SARS-CoV-2
by: Ivette Morales-Salazar, et al.
Published: (2021-11-01)

The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19
by: Miklós Bege, et al.
Published: (2024-02-01)

In Silico Analysis of Peptide-Based Derivatives Containing Bifunctional Warheads Engaging Prime and Non-Prime Subsites to Covalent Binding SARS-CoV-2 Main Protease (M<sup>pro</sup>)
by: Simone Brogi, et al.
Published: (2022-05-01)

In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations
by: Mehreen Ghufran, et al.
Published: (2023-01-01)

Re-Exploring the Ability of Common Docking Programs to Correctly Reproduce the Binding Modes of Non-Covalent Inhibitors of SARS-CoV-2 Protease M<sup>pro</sup>
by: Davide Bassani, et al.
Published: (2022-01-01)

Natural Products from Marine Actinomycete Genus <i>Salinispora</i> Might Inhibit 3CL<sup>pro</sup> and PL<sup>pro</sup> Proteins of SARS-CoV-2: An In Silico Evidence
by: Omkar Pokharkar, et al.
Published: (2023-11-01)

Design of D-Amino Acids SARS-CoV-2 Main Protease Inhibitors Using the Cationic Peptide from Rattlesnake Venom as a Scaffold
by: Raphael J. Eberle, et al.
Published: (2022-04-01)

Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease
by: Roxanna Hajbabaie, et al.
Published: (2021-02-01)

Identification of SARS-CoV-2 Main Protease Inhibitors from a Library of Minor Cannabinoids by Biochemical Inhibition Assay and Surface Plasmon Resonance Characterized Binding Affinity
by: Chang Liu, et al.
Published: (2022-09-01)

Ensemble Docking Coupled to Linear Interaction Energy Calculations for Identification of Coronavirus Main Protease (3CL<sup>pro</sup>) Non-Covalent Small-Molecule Inhibitors
by: Marko Jukič, et al.
Published: (2020-12-01)

Identification of Triazolopyrimidinyl Scaffold SARS-CoV-2 Papain-Like Protease (PL<sup>pro</sup>) Inhibitor
by: Sebastjan Kralj, et al.
Published: (2024-01-01)

Structural Basis for the Inhibition of SARS-CoV-2 M<sup>pro</sup> D48N Mutant by Shikonin and PF-07321332
by: Zhenyu Zhao, et al.
Published: (2023-12-01)

Inhibition of Cysteine Proteases by 6,6′-Dihydroxythiobinupharidine (DTBN) from <i>Nuphar lutea</i>
by: Kamran Waidha, et al.
Published: (2021-08-01)

Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection
by: Praveen P. N. Rao, et al.
Published: (2021-01-01)

SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome
by: Anna Maria Sardanelli, et al.
Published: (2021-03-01)

Unique Structural Fold of LonBA Protease from <i>Bacillus subtilis,</i> a Member of a Newly Identified Subfamily of Lon Proteases
by: Alla Gustchina, et al.
Published: (2022-09-01)

Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies
by: Daoud Safa, et al.
Published: (2021-06-01)

Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
by: Andrea Citarella, et al.
Published: (2023-09-01)

Riboflavin, a Potent Neuroprotective Vitamin: Focus on Flavivirus and Alphavirus Proteases
by: Raphael J. Eberle, et al.
Published: (2022-06-01)

Prioritisation of Compounds for 3CL<sup>pro</sup> Inhibitor Development on SARS-CoV-2 Variants
by: Marko Jukič, et al.
Published: (2021-05-01)

Design, Synthesis and Evaluation of Fused Bicyclo[2.2.2]octene as a Potential Core Scaffold for the Non-Covalent Inhibitors of SARS-CoV-2 3CL<sup>pro</sup> Main Protease
by: Barbara Herlah, et al.
Published: (2022-04-01)

Microencapsulation of a Commercial Food-Grade Protease by Spray Drying in Cross-Linked Chitosan Particles
by: María D. Busto, et al.
Published: (2022-07-01)

Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature’s toolbox of bioactive compounds
by: Io Antonopoulou, et al.
Published: (2022-01-01)

Repurposing of Drugs for SARS-CoV-2 Using Inverse Docking Fingerprints
by: Marko Jukič, et al.
Published: (2021-12-01)

Fluorine Atoms on C<sub>6</sub>H<sub>5</sub>-Corrole Affect the Interaction with M<sup>pro</sup> and PL<sup>pro</sup> Proteases of SARS-CoV-2: Molecular Docking and 2D-QSAR Approaches
by: Otávio Augusto Chaves, et al.
Published: (2022-09-01)

Andrographolide and Deoxyandrographolide Inhibit Protease and IFN-Antagonist Activities of Foot-and-Mouth Disease Virus 3C<sup>pro</sup>
by: Sirin Theerawatanasirikul, et al.
Published: (2022-08-01)

Interaction of Laurusides 1 and 2 with the 3C-like Protease (M<sup>pro</sup>) from Wild-Type and Omicron Variant of SARS-CoV-2: A Molecular Dynamics Study
by: Ida Autiero, et al.
Published: (2023-03-01)

Identification of Phytochemicals from Arabian Peninsula Medicinal Plants as Strong Binders to SARS-CoV-2 Proteases (3CL<sup>Pro</sup> and PL<sup>Pro</sup>) by Molecular Docking and Dynamic Simulation Studies
by: Quaiser Saquib, et al.
Published: (2024-02-01)

Search for Non-Protein Protease Inhibitors Constituted with an Indole and Acetylene Core
by: Marco A. Almaraz-Girón, et al.
Published: (2021-06-01)

Natural Phytochemicals, Luteolin and Isoginkgetin, Inhibit 3C Protease and Infection of FMDV, In Silico and In Vitro
by: Sirin Theerawatanasirikul, et al.
Published: (2021-10-01)

SARS-CoV-2 M<sup>pro</sup> Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies
by: Conrad Fischer, et al.
Published: (2023-01-01)